Global Acne Drugs

Acne Drugs Comprehensive Study by Mode of Administration (Oral, Topical, Injectable), Therapeutic Class (Retinoid, Antibiotic, Hormonal Agent, Combination, Others), Age Group (0-10 years, 11-16 years, 17-25 years, 26-40 years, 41-60 years, 61-80 years, 80+ years) Players and Region - Global Market Outlook to 2028

Acne Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Acne is a common dermatological condition, affecting more than 9.4 million worldwide. Acne refers to a skin disorder that leads to the outbreak of lesions called pimples. Acne drugs helps to reduce oil production, speeding up skin cell turnover, fighting bacterial infection or reducing inflammation which helps prevent scarring. Acne Drugs market is expected to grow exponentially during the forecast period owing to the unhealthy lifestyle among the population. Rise in androgen (estrogen, in women) levels during puberty trigger the onset of this condition by enlarging oil glands under the skin is also driving the acne drug market.This growth is primarily driven by Increasing Prevalence and Severity of Acne .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitUnit
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Kate Somerville (United Kingdom), Differin (United States), Epiduo (United States), Allergan Plc (Ireland), Bayer (Germany), Galderma (Switzerland), Stiefel (United States), Bausch Health (Canada) and Beiersdorf AG. (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In November 2022, Heyday, a forward-thinking consumer products company that prioritizes a digital-first approach to brand development, acquired ZitSticka. ZitSticka is widely recognized for its exceptional range of effective products tailored for acne treatment and prevention. This strategic acquisition reinforces Heyday's significant presence in the personal care industry and positions the company as a frontrunner in the rapidly expanding market segment of acne patches.
In May 2023, Crown Therapeutics, a division of Crown Laboratories, is delighted to unveil the additions to its acclaimed PanOxyl® product line. The expansion includes the introduction of the PM Balancing Repair Moisturizer and the reformulation of the existing AM Oil Control Moisturizer. This development further enhances the diverse and highly regarded portfolio of PanOxyl®.The competitive landscape of acne drugs is characterized by a diverse range of players vying for market share. These companies offer a variety of treatments and products aimed at addressing acne and its associated symptoms. Innovation, research and development, and clinical efficacy are key factors driving competition in this sector. Players in the acne drugs market focus on developing novel formulations, improved delivery systems, and targeted therapeutic approaches to gain a competitive edge. Marketing strategies, pricing, and partnerships with dermatologists and healthcare professionals also play significant roles in capturing market attention and expanding their customer base. Overall, the acne drugs market is highly competitive, with companies constantly striving to meet the evolving needs of consumers and establish themselves as leaders in this space.

Regulatory Insights:
According to the FDA, The final rule lists all permitted active ingredients for OTC topical acne products, and their respective permissible concentrations and ingredient combinations, as set forth in 21 CFR 333.310 and 21 CFR 333.320. The monograph, as amended by the final rule, permits the use of three single active ingredients and two combinations of active ingredients.

Influencing Trend:
Rising Adoption of Skin Care Products through E-commerce

Market Growth Drivers:
Increasing Prevalence and Severity of Acne, Unhygienic Lifestyle and Excessive Production of Oil from Sebaceous Glands have Increased the Prevalence of Acne and Rise in Concern for Facial Aesthetics

Challenges:
Side Effects Associated with the Intake of Acne Drugs such as Redness of the Skin, Skin Rash, etc

Restraints:
Stringent Government Rules and Regulation for Acne Drugs

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Acne Drugs Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Acne Drugs Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Acne Drugs players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Acne Drugs Study Sheds Light on
— The Acne Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Acne Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Acne Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Mode of Administration
  • Oral
  • Topical
  • Injectable

By Therapeutic Class
  • Retinoid
  • Antibiotic
  • Hormonal Agent
  • Combination
  • Others

By Age Group
  • 0-10 years
  • 11-16 years
  • 17-25 years
  • 26-40 years
  • 41-60 years
  • 61-80 years
  • 80+ years

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence and Severity of Acne
      • 3.2.2. Unhygienic Lifestyle and Excessive Production of Oil from Sebaceous Glands have Increased the Prevalence of Acne
      • 3.2.3. Rise in Concern for Facial Aesthetics
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Associated with the Intake of Acne Drugs such as Redness of the Skin, Skin Rash, etc
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption of Skin Care Products through E-commerce
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acne Drugs, by Mode of Administration, Therapeutic Class, Age Group and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Acne Drugs (Value)
      • 5.2.1. Global Acne Drugs by: Mode of Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Topical
        • 5.2.1.3. Injectable
      • 5.2.2. Global Acne Drugs by: Therapeutic Class (Value)
        • 5.2.2.1. Retinoid
        • 5.2.2.2. Antibiotic
        • 5.2.2.3. Hormonal Agent
        • 5.2.2.4. Combination
        • 5.2.2.5. Others
      • 5.2.3. Global Acne Drugs by: Age Group (Value)
        • 5.2.3.1. 0-10 years
        • 5.2.3.2. 11-16 years
        • 5.2.3.3. 17-25 years
        • 5.2.3.4. 26-40 years
        • 5.2.3.5. 41-60 years
        • 5.2.3.6. 61-80 years
        • 5.2.3.7. 80+ years
      • 5.2.4. Global Acne Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Acne Drugs (Volume)
      • 5.3.1. Global Acne Drugs by: Mode of Administration (Volume)
        • 5.3.1.1. Oral
        • 5.3.1.2. Topical
        • 5.3.1.3. Injectable
      • 5.3.2. Global Acne Drugs by: Therapeutic Class (Volume)
        • 5.3.2.1. Retinoid
        • 5.3.2.2. Antibiotic
        • 5.3.2.3. Hormonal Agent
        • 5.3.2.4. Combination
        • 5.3.2.5. Others
      • 5.3.3. Global Acne Drugs by: Age Group (Volume)
        • 5.3.3.1. 0-10 years
        • 5.3.3.2. 11-16 years
        • 5.3.3.3. 17-25 years
        • 5.3.3.4. 26-40 years
        • 5.3.3.5. 41-60 years
        • 5.3.3.6. 61-80 years
        • 5.3.3.7. 80+ years
      • 5.3.4. Global Acne Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Acne Drugs (Price)
  • 6. Acne Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Kate Somerville (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Differin (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Epiduo (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan Plc (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Galderma (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Stiefel (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bausch Health (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Beiersdorf AG. (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Acne Drugs Sale, by Mode of Administration, Therapeutic Class, Age Group and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Acne Drugs (Value)
      • 7.2.1. Global Acne Drugs by: Mode of Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Topical
        • 7.2.1.3. Injectable
      • 7.2.2. Global Acne Drugs by: Therapeutic Class (Value)
        • 7.2.2.1. Retinoid
        • 7.2.2.2. Antibiotic
        • 7.2.2.3. Hormonal Agent
        • 7.2.2.4. Combination
        • 7.2.2.5. Others
      • 7.2.3. Global Acne Drugs by: Age Group (Value)
        • 7.2.3.1. 0-10 years
        • 7.2.3.2. 11-16 years
        • 7.2.3.3. 17-25 years
        • 7.2.3.4. 26-40 years
        • 7.2.3.5. 41-60 years
        • 7.2.3.6. 61-80 years
        • 7.2.3.7. 80+ years
      • 7.2.4. Global Acne Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Acne Drugs (Volume)
      • 7.3.1. Global Acne Drugs by: Mode of Administration (Volume)
        • 7.3.1.1. Oral
        • 7.3.1.2. Topical
        • 7.3.1.3. Injectable
      • 7.3.2. Global Acne Drugs by: Therapeutic Class (Volume)
        • 7.3.2.1. Retinoid
        • 7.3.2.2. Antibiotic
        • 7.3.2.3. Hormonal Agent
        • 7.3.2.4. Combination
        • 7.3.2.5. Others
      • 7.3.3. Global Acne Drugs by: Age Group (Volume)
        • 7.3.3.1. 0-10 years
        • 7.3.3.2. 11-16 years
        • 7.3.3.3. 17-25 years
        • 7.3.3.4. 26-40 years
        • 7.3.3.5. 41-60 years
        • 7.3.3.6. 61-80 years
        • 7.3.3.7. 80+ years
      • 7.3.4. Global Acne Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Acne Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acne Drugs: by Mode of Administration(USD Million)
  • Table 2. Acne Drugs Oral , by Region USD Million (2017-2022)
  • Table 3. Acne Drugs Topical , by Region USD Million (2017-2022)
  • Table 4. Acne Drugs Injectable , by Region USD Million (2017-2022)
  • Table 5. Acne Drugs: by Therapeutic Class(USD Million)
  • Table 6. Acne Drugs Retinoid , by Region USD Million (2017-2022)
  • Table 7. Acne Drugs Antibiotic , by Region USD Million (2017-2022)
  • Table 8. Acne Drugs Hormonal Agent , by Region USD Million (2017-2022)
  • Table 9. Acne Drugs Combination , by Region USD Million (2017-2022)
  • Table 10. Acne Drugs Others , by Region USD Million (2017-2022)
  • Table 11. Acne Drugs: by Age Group(USD Million)
  • Table 12. Acne Drugs 0-10 years , by Region USD Million (2017-2022)
  • Table 13. Acne Drugs 11-16 years , by Region USD Million (2017-2022)
  • Table 14. Acne Drugs 17-25 years , by Region USD Million (2017-2022)
  • Table 15. Acne Drugs 26-40 years , by Region USD Million (2017-2022)
  • Table 16. Acne Drugs 41-60 years , by Region USD Million (2017-2022)
  • Table 17. Acne Drugs 61-80 years , by Region USD Million (2017-2022)
  • Table 18. Acne Drugs 80+ years , by Region USD Million (2017-2022)
  • Table 19. South America Acne Drugs, by Country USD Million (2017-2022)
  • Table 20. South America Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 21. South America Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 22. South America Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 23. Brazil Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 24. Brazil Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 25. Brazil Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 26. Argentina Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 27. Argentina Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 28. Argentina Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 29. Rest of South America Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 30. Rest of South America Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 31. Rest of South America Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 32. Asia Pacific Acne Drugs, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 34. Asia Pacific Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 35. Asia Pacific Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 36. China Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 37. China Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 38. China Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 39. Japan Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 40. Japan Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 41. Japan Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 42. India Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 43. India Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 44. India Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 45. South Korea Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 46. South Korea Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 47. South Korea Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 48. Taiwan Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 49. Taiwan Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 50. Taiwan Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 51. Australia Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 52. Australia Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 53. Australia Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 55. Rest of Asia-Pacific Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 57. Europe Acne Drugs, by Country USD Million (2017-2022)
  • Table 58. Europe Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 59. Europe Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 60. Europe Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 61. Germany Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 62. Germany Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 63. Germany Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 64. France Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 65. France Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 66. France Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 67. Italy Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 68. Italy Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 69. Italy Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 70. United Kingdom Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 71. United Kingdom Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 72. United Kingdom Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 73. Netherlands Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 74. Netherlands Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 75. Netherlands Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 76. Rest of Europe Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 77. Rest of Europe Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 78. Rest of Europe Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 79. MEA Acne Drugs, by Country USD Million (2017-2022)
  • Table 80. MEA Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 81. MEA Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 82. MEA Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 83. Middle East Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 84. Middle East Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 85. Middle East Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 86. Africa Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 87. Africa Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 88. Africa Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 89. North America Acne Drugs, by Country USD Million (2017-2022)
  • Table 90. North America Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 91. North America Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 92. North America Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 93. United States Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 94. United States Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 95. United States Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 96. Canada Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 97. Canada Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 98. Canada Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 99. Mexico Acne Drugs, by Mode of Administration USD Million (2017-2022)
  • Table 100. Mexico Acne Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 101. Mexico Acne Drugs, by Age Group USD Million (2017-2022)
  • Table 102. Acne Drugs Sales: by Mode of Administration(Unit)
  • Table 103. Acne Drugs Sales Oral , by Region Unit (2017-2022)
  • Table 104. Acne Drugs Sales Topical , by Region Unit (2017-2022)
  • Table 105. Acne Drugs Sales Injectable , by Region Unit (2017-2022)
  • Table 106. Acne Drugs Sales: by Therapeutic Class(Unit)
  • Table 107. Acne Drugs Sales Retinoid , by Region Unit (2017-2022)
  • Table 108. Acne Drugs Sales Antibiotic , by Region Unit (2017-2022)
  • Table 109. Acne Drugs Sales Hormonal Agent , by Region Unit (2017-2022)
  • Table 110. Acne Drugs Sales Combination , by Region Unit (2017-2022)
  • Table 111. Acne Drugs Sales Others , by Region Unit (2017-2022)
  • Table 112. Acne Drugs Sales: by Age Group(Unit)
  • Table 113. Acne Drugs Sales 0-10 years , by Region Unit (2017-2022)
  • Table 114. Acne Drugs Sales 11-16 years , by Region Unit (2017-2022)
  • Table 115. Acne Drugs Sales 17-25 years , by Region Unit (2017-2022)
  • Table 116. Acne Drugs Sales 26-40 years , by Region Unit (2017-2022)
  • Table 117. Acne Drugs Sales 41-60 years , by Region Unit (2017-2022)
  • Table 118. Acne Drugs Sales 61-80 years , by Region Unit (2017-2022)
  • Table 119. Acne Drugs Sales 80+ years , by Region Unit (2017-2022)
  • Table 120. South America Acne Drugs Sales, by Country Unit (2017-2022)
  • Table 121. South America Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 122. South America Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 123. South America Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 124. Brazil Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 125. Brazil Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 126. Brazil Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 127. Argentina Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 128. Argentina Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 129. Argentina Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 130. Rest of South America Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 131. Rest of South America Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 132. Rest of South America Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 133. Asia Pacific Acne Drugs Sales, by Country Unit (2017-2022)
  • Table 134. Asia Pacific Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 135. Asia Pacific Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 136. Asia Pacific Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 137. China Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 138. China Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 139. China Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 140. Japan Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 141. Japan Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 142. Japan Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 143. India Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 144. India Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 145. India Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 146. South Korea Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 147. South Korea Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 148. South Korea Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 149. Taiwan Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 150. Taiwan Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 151. Taiwan Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 152. Australia Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 153. Australia Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 154. Australia Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 155. Rest of Asia-Pacific Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 156. Rest of Asia-Pacific Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 157. Rest of Asia-Pacific Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 158. Europe Acne Drugs Sales, by Country Unit (2017-2022)
  • Table 159. Europe Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 160. Europe Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 161. Europe Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 162. Germany Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 163. Germany Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 164. Germany Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 165. France Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 166. France Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 167. France Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 168. Italy Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 169. Italy Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 170. Italy Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 171. United Kingdom Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 172. United Kingdom Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 173. United Kingdom Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 174. Netherlands Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 175. Netherlands Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 176. Netherlands Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 177. Rest of Europe Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 178. Rest of Europe Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 179. Rest of Europe Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 180. MEA Acne Drugs Sales, by Country Unit (2017-2022)
  • Table 181. MEA Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 182. MEA Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 183. MEA Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 184. Middle East Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 185. Middle East Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 186. Middle East Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 187. Africa Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 188. Africa Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 189. Africa Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 190. North America Acne Drugs Sales, by Country Unit (2017-2022)
  • Table 191. North America Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 192. North America Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 193. North America Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 194. United States Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 195. United States Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 196. United States Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 197. Canada Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 198. Canada Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 199. Canada Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 200. Mexico Acne Drugs Sales, by Mode of Administration Unit (2017-2022)
  • Table 201. Mexico Acne Drugs Sales, by Therapeutic Class Unit (2017-2022)
  • Table 202. Mexico Acne Drugs Sales, by Age Group Unit (2017-2022)
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Acne Drugs: by Mode of Administration(USD Million)
  • Table 213. Acne Drugs Oral , by Region USD Million (2023-2028)
  • Table 214. Acne Drugs Topical , by Region USD Million (2023-2028)
  • Table 215. Acne Drugs Injectable , by Region USD Million (2023-2028)
  • Table 216. Acne Drugs: by Therapeutic Class(USD Million)
  • Table 217. Acne Drugs Retinoid , by Region USD Million (2023-2028)
  • Table 218. Acne Drugs Antibiotic , by Region USD Million (2023-2028)
  • Table 219. Acne Drugs Hormonal Agent , by Region USD Million (2023-2028)
  • Table 220. Acne Drugs Combination , by Region USD Million (2023-2028)
  • Table 221. Acne Drugs Others , by Region USD Million (2023-2028)
  • Table 222. Acne Drugs: by Age Group(USD Million)
  • Table 223. Acne Drugs 0-10 years , by Region USD Million (2023-2028)
  • Table 224. Acne Drugs 11-16 years , by Region USD Million (2023-2028)
  • Table 225. Acne Drugs 17-25 years , by Region USD Million (2023-2028)
  • Table 226. Acne Drugs 26-40 years , by Region USD Million (2023-2028)
  • Table 227. Acne Drugs 41-60 years , by Region USD Million (2023-2028)
  • Table 228. Acne Drugs 61-80 years , by Region USD Million (2023-2028)
  • Table 229. Acne Drugs 80+ years , by Region USD Million (2023-2028)
  • Table 230. South America Acne Drugs, by Country USD Million (2023-2028)
  • Table 231. South America Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 232. South America Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 233. South America Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 234. Brazil Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 235. Brazil Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 236. Brazil Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 237. Argentina Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 238. Argentina Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 239. Argentina Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 240. Rest of South America Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 241. Rest of South America Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 242. Rest of South America Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 243. Asia Pacific Acne Drugs, by Country USD Million (2023-2028)
  • Table 244. Asia Pacific Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 245. Asia Pacific Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 246. Asia Pacific Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 247. China Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 248. China Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 249. China Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 250. Japan Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 251. Japan Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 252. Japan Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 253. India Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 254. India Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 255. India Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 256. South Korea Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 257. South Korea Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 258. South Korea Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 259. Taiwan Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 260. Taiwan Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 261. Taiwan Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 262. Australia Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 263. Australia Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 264. Australia Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 265. Rest of Asia-Pacific Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 266. Rest of Asia-Pacific Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 267. Rest of Asia-Pacific Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 268. Europe Acne Drugs, by Country USD Million (2023-2028)
  • Table 269. Europe Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 270. Europe Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 271. Europe Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 272. Germany Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 273. Germany Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 274. Germany Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 275. France Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 276. France Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 277. France Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 278. Italy Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 279. Italy Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 280. Italy Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 281. United Kingdom Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 282. United Kingdom Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 283. United Kingdom Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 284. Netherlands Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 285. Netherlands Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 286. Netherlands Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 287. Rest of Europe Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 288. Rest of Europe Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 289. Rest of Europe Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 290. MEA Acne Drugs, by Country USD Million (2023-2028)
  • Table 291. MEA Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 292. MEA Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 293. MEA Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 294. Middle East Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 295. Middle East Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 296. Middle East Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 297. Africa Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 298. Africa Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 299. Africa Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 300. North America Acne Drugs, by Country USD Million (2023-2028)
  • Table 301. North America Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 302. North America Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 303. North America Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 304. United States Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 305. United States Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 306. United States Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 307. Canada Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 308. Canada Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 309. Canada Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 310. Mexico Acne Drugs, by Mode of Administration USD Million (2023-2028)
  • Table 311. Mexico Acne Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 312. Mexico Acne Drugs, by Age Group USD Million (2023-2028)
  • Table 313. Acne Drugs Sales: by Mode of Administration(Unit)
  • Table 314. Acne Drugs Sales Oral , by Region Unit (2023-2028)
  • Table 315. Acne Drugs Sales Topical , by Region Unit (2023-2028)
  • Table 316. Acne Drugs Sales Injectable , by Region Unit (2023-2028)
  • Table 317. Acne Drugs Sales: by Therapeutic Class(Unit)
  • Table 318. Acne Drugs Sales Retinoid , by Region Unit (2023-2028)
  • Table 319. Acne Drugs Sales Antibiotic , by Region Unit (2023-2028)
  • Table 320. Acne Drugs Sales Hormonal Agent , by Region Unit (2023-2028)
  • Table 321. Acne Drugs Sales Combination , by Region Unit (2023-2028)
  • Table 322. Acne Drugs Sales Others , by Region Unit (2023-2028)
  • Table 323. Acne Drugs Sales: by Age Group(Unit)
  • Table 324. Acne Drugs Sales 0-10 years , by Region Unit (2023-2028)
  • Table 325. Acne Drugs Sales 11-16 years , by Region Unit (2023-2028)
  • Table 326. Acne Drugs Sales 17-25 years , by Region Unit (2023-2028)
  • Table 327. Acne Drugs Sales 26-40 years , by Region Unit (2023-2028)
  • Table 328. Acne Drugs Sales 41-60 years , by Region Unit (2023-2028)
  • Table 329. Acne Drugs Sales 61-80 years , by Region Unit (2023-2028)
  • Table 330. Acne Drugs Sales 80+ years , by Region Unit (2023-2028)
  • Table 331. South America Acne Drugs Sales, by Country Unit (2023-2028)
  • Table 332. South America Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 333. South America Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 334. South America Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 335. Brazil Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 336. Brazil Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 337. Brazil Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 338. Argentina Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 339. Argentina Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 340. Argentina Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 341. Rest of South America Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 342. Rest of South America Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 343. Rest of South America Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 344. Asia Pacific Acne Drugs Sales, by Country Unit (2023-2028)
  • Table 345. Asia Pacific Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 346. Asia Pacific Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 347. Asia Pacific Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 348. China Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 349. China Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 350. China Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 351. Japan Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 352. Japan Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 353. Japan Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 354. India Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 355. India Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 356. India Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 357. South Korea Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 358. South Korea Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 359. South Korea Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 360. Taiwan Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 361. Taiwan Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 362. Taiwan Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 363. Australia Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 364. Australia Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 365. Australia Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 366. Rest of Asia-Pacific Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 367. Rest of Asia-Pacific Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 368. Rest of Asia-Pacific Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 369. Europe Acne Drugs Sales, by Country Unit (2023-2028)
  • Table 370. Europe Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 371. Europe Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 372. Europe Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 373. Germany Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 374. Germany Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 375. Germany Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 376. France Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 377. France Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 378. France Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 379. Italy Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 380. Italy Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 381. Italy Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 382. United Kingdom Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 383. United Kingdom Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 384. United Kingdom Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 385. Netherlands Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 386. Netherlands Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 387. Netherlands Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 388. Rest of Europe Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 389. Rest of Europe Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 390. Rest of Europe Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 391. MEA Acne Drugs Sales, by Country Unit (2023-2028)
  • Table 392. MEA Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 393. MEA Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 394. MEA Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 395. Middle East Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 396. Middle East Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 397. Middle East Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 398. Africa Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 399. Africa Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 400. Africa Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 401. North America Acne Drugs Sales, by Country Unit (2023-2028)
  • Table 402. North America Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 403. North America Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 404. North America Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 405. United States Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 406. United States Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 407. United States Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 408. Canada Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 409. Canada Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 410. Canada Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 411. Mexico Acne Drugs Sales, by Mode of Administration Unit (2023-2028)
  • Table 412. Mexico Acne Drugs Sales, by Therapeutic Class Unit (2023-2028)
  • Table 413. Mexico Acne Drugs Sales, by Age Group Unit (2023-2028)
  • Table 414. Research Programs/Design for This Report
  • Table 415. Key Data Information from Secondary Sources
  • Table 416. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acne Drugs: by Mode of Administration USD Million (2017-2022)
  • Figure 5. Global Acne Drugs: by Therapeutic Class USD Million (2017-2022)
  • Figure 6. Global Acne Drugs: by Age Group USD Million (2017-2022)
  • Figure 7. South America Acne Drugs Share (%), by Country
  • Figure 8. Asia Pacific Acne Drugs Share (%), by Country
  • Figure 9. Europe Acne Drugs Share (%), by Country
  • Figure 10. MEA Acne Drugs Share (%), by Country
  • Figure 11. North America Acne Drugs Share (%), by Country
  • Figure 12. Global Acne Drugs: by Mode of Administration Unit (2017-2022)
  • Figure 13. Global Acne Drugs: by Therapeutic Class Unit (2017-2022)
  • Figure 14. Global Acne Drugs: by Age Group Unit (2017-2022)
  • Figure 15. South America Acne Drugs Share (%), by Country
  • Figure 16. Asia Pacific Acne Drugs Share (%), by Country
  • Figure 17. Europe Acne Drugs Share (%), by Country
  • Figure 18. MEA Acne Drugs Share (%), by Country
  • Figure 19. North America Acne Drugs Share (%), by Country
  • Figure 20. Global Acne Drugs share by Players 2022 (%)
  • Figure 21. Global Acne Drugs share by Players (Top 3) 2022(%)
  • Figure 22. Global Acne Drugs share by Players (Top 5) 2022(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Kate Somerville (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. Kate Somerville (United Kingdom) Revenue: by Geography 2022
  • Figure 26. Differin (United States) Revenue, Net Income and Gross profit
  • Figure 27. Differin (United States) Revenue: by Geography 2022
  • Figure 28. Epiduo (United States) Revenue, Net Income and Gross profit
  • Figure 29. Epiduo (United States) Revenue: by Geography 2022
  • Figure 30. Allergan Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 31. Allergan Plc (Ireland) Revenue: by Geography 2022
  • Figure 32. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Bayer (Germany) Revenue: by Geography 2022
  • Figure 34. Galderma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Galderma (Switzerland) Revenue: by Geography 2022
  • Figure 36. Stiefel (United States) Revenue, Net Income and Gross profit
  • Figure 37. Stiefel (United States) Revenue: by Geography 2022
  • Figure 38. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 39. Bausch Health (Canada) Revenue: by Geography 2022
  • Figure 40. Beiersdorf AG. (Germany) Revenue, Net Income and Gross profit
  • Figure 41. Beiersdorf AG. (Germany) Revenue: by Geography 2022
  • Figure 42. Global Acne Drugs: by Mode of Administration USD Million (2023-2028)
  • Figure 43. Global Acne Drugs: by Therapeutic Class USD Million (2023-2028)
  • Figure 44. Global Acne Drugs: by Age Group USD Million (2023-2028)
  • Figure 45. South America Acne Drugs Share (%), by Country
  • Figure 46. Asia Pacific Acne Drugs Share (%), by Country
  • Figure 47. Europe Acne Drugs Share (%), by Country
  • Figure 48. MEA Acne Drugs Share (%), by Country
  • Figure 49. North America Acne Drugs Share (%), by Country
  • Figure 50. Global Acne Drugs: by Mode of Administration Unit (2023-2028)
  • Figure 51. Global Acne Drugs: by Therapeutic Class Unit (2023-2028)
  • Figure 52. Global Acne Drugs: by Age Group Unit (2023-2028)
  • Figure 53. South America Acne Drugs Share (%), by Country
  • Figure 54. Asia Pacific Acne Drugs Share (%), by Country
  • Figure 55. Europe Acne Drugs Share (%), by Country
  • Figure 56. MEA Acne Drugs Share (%), by Country
  • Figure 57. North America Acne Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Kate Somerville (United Kingdom)
  • Differin (United States)
  • Epiduo (United States)
  • Allergan Plc (Ireland)
  • Bayer (Germany)
  • Galderma (Switzerland)
  • Stiefel (United States)
  • Bausch Health (Canada)
  • Beiersdorf AG. (Germany)
Additional players considered in the study are as follows:
Belli , Doudou Kang , Pikangwang , Cetaphil , ABSORICA
Select User Access Type

Key Highlights of Report


Jul 2023 223 Pages 55 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Acne Drugs Quantitative research analysis
Global Acne Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Acne Drugs Market are Kate Somerville (United Kingdom), Differin (United States), Epiduo (United States), Allergan Plc (Ireland), Bayer (Germany), Galderma (Switzerland), Stiefel (United States), Bausch Health (Canada) and Beiersdorf AG. (Germany) etc.
AMA Research predicts that United States Players will contribute to the maximum growth of Global Acne Drugs market throughout the forecasted period.

Know More About Global Acne Drugs Report?

Have a Query? Click Here

Other Related Reports

Hepatitis A Vaccine Comprehensive Study by Type (Liver Inactivated Vaccine, Live Attenuated Vaccine), Application (Hospitals & Clinics,, Others (Organizations Associated with Government Vaccinations ...
$ 3750
Anti-Suicide Drug Comprehensive Study by Type (Anti-Depressants and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), Application (Hospital, Clinic, Home Use), Distributi...
$ 3800
Actinic Keratosis Drugs Comprehensive Study by Type (Nucleoside metabolic inhibitors, Immunomodulators, Photosensitizing agents, NSAIDs), Way of Intake (Tablets, Cream, Other), End User (Hospitals, C...
$ 3450
Medium-chain Triglycerides Comprehensive Study by Type (Caprylic Acid, Capric Acid, Lauric Acid, Caproic Acid), Application (Nutritional Diet, Personal Care, Pharmaceuticals, Sports Drinks, Infant Fo...
$ 3450
Antacid Tablet Comprehensive Study by Type (Ca-based, Mg-based, Mixed), Application (In-Patient, Out-Patient), Distribution Chanel (Hospital Pharmacies, Retail Pharmacies, Others) Players and Region ...
$ 3500
Neisseria meningitidis Infections Drug Comprehensive Study by Type (Penicillin, Ampicillin, Ceftriaxone), End-users (Hospital, Clinic, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmac...
$ 3350